

THE FETAL-PLACENTAL UNIT AS AN ALLOGRAFT:

BREAKAGE OF THE FETAL MATERNAL TOLERANCE IN PREECLAPSIA



I. de Luca Brunori*, A. R. Genazzani*

II. Collaborators

L. Battini*; M. Simonelli*; V. Valentino*; E. Brunori **; M. Curcio§;

M. Mariotti§

*Dept. of Obstetrics and Gynecology - University of Pisa - Italy

**Stella Maris Foundation - IRCCS - Tirrenia - Italy

§ Immunogenetics Laboratory - S. Chiara Hospital - Pisa - Italy

This study highlights the greatest message addressed by pregnancy:

"THE TOLERANCE OF BIODIVERSITY"

In fact, the placenta acts as an immunological barrier between the mother and fetal "graft" allowing two antigenically different organisms to tolerate one another

It is clear that any damage to this barrier from various ischemic risk factors (metabolic, hormonal, genetic, immunological) may be responsible for lesions of the syncytiotrophoblast and villous vessels endothelial cells as we demonstrated by electron microscopy.


J. Anat. Embriol., 103, 202, 1998

Ultrastructural study of the human placental endothelium in preeclampsia

de Luca Brunori I., Lenzi P., Paparelli A. et al.







Clin Exp Obst Gyn., 21, 228-230, 1994.

Gestosis and fetal rejection: immunopathogenetic role of HLA-DR

de Luca Brunori I., Battini L., Simonelli M. et al.


To verify this rejection's hypothesis, we examined placentae from preeclamptic patients and controls by immunohistochemical technique and HLA-DR monoclonal antibody.


Clin Exp Obst Gyn., 21, 192-194, 1994.


Immunohistochemical study of placental endothelium in physiologic and gestosis-complicated pregnancies by HLA-DR monoclonal antibodies


de Luca Brunori I., Battini L., Simonelli M. et al.

HLA-DR falls under human class II of the Major Histocompatibility Complex (MHC) and it identifies several elements involved in activating and maintaining immunitary response (limphocytes, macrophages, cell T activated, endothelial cells). Therefore, HLA-DR plays a fundamental role in self and nonself recognition and in rejective reaction.









To understand the mechanism at the basis of such an evident immunological reaction in Preeclampsia, we undertook a study to evaluate if Preeeclampsia, like transplant rejection, could be related to the immunological role of the HLA-DR Antigens.

Hum.Reprod. 15, 1807-1812, 2000.

Increased HLA-DR homozygosity associated with preeclampsia

de Luca Brunori, I., Battini, M. Simonelli et al.

In this study HLA-DR was typed in


- 70 preeclamptic women, their partners
- 70 healthy control couples

by serological Terasaki technique.

- 20 cases out of the preeclamptic couples
- 20 control couples were typed

by low resolution PCR

HLA-DR TYPING RESULTS



HOMOZYGOSITY DISTRIBUTION

	20	P	
	N (%)	N (%)	N (%)
preeclampsia	26 (37.1)	22 (31.4)	20 (28.6)
controls	1 (1.4)	5 (7.1)	4 (5.7)

HLA-DR ANTIGENS VARIETY


HLA-DR	4	3	2	1
preeclampsia	0	27	40	3
controls	37	28	5	0

These results show that parents associated with preeclamptic pregnancies generally possess homozygosity and /or a small total number (less than 3) of different HLA-DR types than control couples according to Redman et all. 1978

Prenat. Neonat. Med 2 (1997), 325-328

INCREASED V-CAM 1 PLASMATIC LEVELS IN EPH GESTOSIS: A MARKER OF FETAL REJECTION?

I. de Luca Brunori, L. Battini, M. Simonelli, A.R. Genazzani






Fig. 2. Levels of YCAM-1 and creatinine were monitored in a patient following renal allograft at day 0. YCAM-1 levels appeared to rise coincident with, or slightly before, the rise in creatinine, the routine monitor of graft function. Information courtesy of Prof. A. Rees and Dr. J. Hughes, Hammersmith Hospital, London, UK.

DISCUSSION

Redman et al. (1978) found maternal homozygosity HLA-A and B in severe preeclampsia and asserted, in agreement with Jenkins et al., that the reduced HLA-Class I antigenical variety between partners could be the cause of the failure of maternal protective reaction

maternal immunological failure



impaired trophoblastic implantation



high resistance haemocirculatory placental district



severe endothelial damage

HLA-DR homozygosity

Reduced antigenical variety



Failure of maternal immunological protective reaction

Preeclampsia

This highlights an important message:

Reproductive outcome
is particularly successful in
couples of heterozygous partners.

Biodiversity enhances survival and reproduction









Welcome to biodiversity















UPDATE

HLA-DRβ1 alleles DNA sequencing: preliminary results

In this update we have examined the 2nd exon of the human gene, HLA-DRβ1, on the short arm of the cromosome 6 using the DNA sequence-based typing (S-BT) PCR



Match-tools genetic program

Sample: 1881 Preliminary Report	xact match	to: DRB1*1	Library: D		gs Below.		
Files : 1881							
	2						
Polymorphic Position F	Report						
				222222222			nucleotide
4444577788 8888999900							number
0268747802 4789147912	5902367930	3692990123	4578969789	0124568012	0123402478	40	
GGCTTGTCTG CATATCACAG	GAAGTGCTGT	GCTCGGATGC	CGGTAGAAGA	CGACGGCGCG	CCTACGGTKK	CA	<> 1881
consensus							
							> 1881
							DRB1*1301/1302

Differently from other techniques like SSO-PCR or SSP-PCR, in which the alleles discrimination is indirectly performed, the DNA sequencing allows us to directly read the nucleotides sequences occurring in the alleles.

Then it is possible to truly identify the real homozygosity whereas the other techniques were only able to evaluate the presumed homozygosity

CASES STUDY

Study group: 56 couples of preeclamptic

women

Control group: 64 couples of physiologic

pregnant women

HLA-DRβ1 TYPING RESULTS



preeclampsia



controls

Homozygosity

34.9%

preeclampsia

94.8%

controls

Heterozygosity

P<0.00001

The HLA-DRβ1 second exon sequencing has demonstrated:

- the presence of a real homozygosity in preeclampsia
- the not recurrence of a particular known HLA-DRβ1 allele
- the absence of a new HLA-DRβ1 allele
- the absence of punctiform mutations

HLA-DRβ1 homozygosity

Preeclampsia

Couple's disease

SUMMARIZING


from our results various evidences seem to confirm the hypothesis of a "fetal rejection in preeclampsia"

1) The ultra-microscopical evidence of the placental endothelial breakage in preeclampsia

2) The immunohistochemical evidence of the intense and widespread HLA-DR antigens expression in placentae from preeclampsia versus controls

- 3) The significant HLA-DR homozygosity excess in Couples of preeclamptic women versus controls, as confirmed also by <u>DNA-sequencing</u>.
- 4) The significant increase of V-CAM 1 plasmatic levels, as demonstrated in other graft rejective reactions.

5) Last, but not least, the clinical evidence that preeclamptic syndrome, quickly disappears after pregnancy interruption, as the fetus could be the cause of a maternal rejective reaction



THE YOUR YOUR ATTENTION